Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma

NCT03215524 is registered in ClinicalTrials.gov with Canadian Myeloma Research Group as lead sponsor.

NCT NCT03215524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03215524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma
Lead sponsor
Canadian Myeloma Research Group
Phase
Phase 2
Overall status
Completed
Start date
October 25, 2017
Completion date
June 24, 2022
Enrollment
120 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma